Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Paladin launches Silenor in Canada
Silenor, which is not a controlled substance, will be made available in 3mg or 6mg oral tablets. Paladin interim president and chief executive officer Mark Beaudet said, "Canadians
Silenor, which is not a controlled substance, will be made available in 3mg or 6mg oral tablets. Paladin interim president and chief executive officer Mark Beaudet said, "Canadians
The US-based nutraceutical company said people who have an allergy or sensitivity to either allergen run the risk of serious or life-threatening allergic reaction if this product is
The LIMS system tracks the multiple next-generation sequencing (NGS) platform workflows from request with the help of secondary analysis. Sapio Sciences VP Kevin Cramer said, "We look forward
Everycell, developed by a team of cell health and aging experts in partnership with GMP manufacturers, consists of over 90 essential phytonutrients, vitamins and minerals that the body
The AB-rated phenoxybenzamine hydrochloride capsule is the authorized generic of Dibenzyline. Prasco chief executive officer Chris Arington said, "Patients and customers alike benefit from WellSpring’s commitment to maintaining
As per the deal, Batavia gains exclusive license to the technology developed at CellaGenics, an UvA Holding company. Batavia CEO Menzo Havenga said, "We are very pleased that
ACLIFORM/COPD is the second pivotal trial designed to assess the safety and efficacy of aclidinium bromide (LAMA) and formoterol fumarate (LABA) fixed dose combinations, delivered in the Pressair
The study included 44 patients with untreated CLL and 53 patients with relapsed CLL. 87% of total patients completed the full treatment course of six cycles. A 95%
The agreement provides Maruishi with exclusive rights to develop, manufacture and commercialize Cara’s CR845 for acute pain and uremic pruritus indications in Japan. Cara Therapeutics CEO Derek Chalmers
Under the terms of the agreement, Cipher will receive an upfront payment and is eligible for additional milestones based upon regulatory approval in Brazil and Mexico. CIP-TRAMADOL ER